Ellen B. Roecker

Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial

Shlomo Shinnar, Avital Cnaan, Fengming Hu, Peggy O. Clark et autres

OBJECTIVE: To determine incidence and early predictors of generalized tonic-clonic seizures (GTCs) in children with childhood absence epilepsy (CAE). METHODS: Occurrence of GTCs was determined in 446 children with CAE who participated in a randomized clinical trial comparing ethosuximide, lamotrigine, and valproate …

us (code pays fourni par la source)

Improvement in Kidney Function: A Real Occurrence

Levin Nw, Ornt Db, Andreas Pierratos, Pipkin Mf et autres

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

Ronald J. Oudiz, Nazzareno Galiè, Horst Olschewski, Adaani Frost et autres

us, it, at, de (code pays fourni par la source)

Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

Marco Metra, Eric J. Eichhorn, William T. Abraham, Jennifer V. Linseman et autres

AIMS: Use of inotropic agents in patients with heart failure (HF) has been limited by adverse effects on outcomes. However, administration of positive inotropes at lower doses and concomitant treatment with beta-blockers might increase benefit-risk ratio. We investigated the effects of low …

it, us, de, cl, fr, ca, ru, ar, gb, se, pl (code pays fourni par la source)

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

Nazzareno Galiè, Horst Olschewski, Ronald J. Oudiz, Adaani Frost et autres

BACKGROUND: Ambrisentan is a propanoic acid-based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension. METHODS AND RESULTS: Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study 1 and 2 (ARIES-1 and ARIES-2) were concurrent, double-blind, placebo-controlled …

de (code pays fourni par la source)

Are β-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study

Henry Krum, Paul Mohaçsi, Hugo A. Katus, Michał Tendera et autres

au, ch, de, pl, ca, us (code pays fourni par la source)

Rationale and Design of the Enoximone Clinical Trials Program

Brian D. Lowes, Simon F. Shakar, Marco Metra, Arthur M. Feldman et autres

us, it (code pays fourni par la source)

Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors

Henry Krum, Steven Joseph Haas, Eric J. Eichhorn, Jalal K. Ghali et autres

AIMS: Beta-blockers (BBs) confer significant prognostic benefit in patients (pts) with systolic chronic heart failure (CHF). However, major trials have thus far studied BBs mainly in addition to ACE-Inhibitors or angiotensin receptor blockers (ARBs) as background therapy. The magnitude of the prognostic …

au, us, fr, de, se (code pays fourni par la source)

Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure

Jean L. Rouleau, Ellen B. Roecker, Michał Tendera, Paul Mohaçsi et autres

ca, us, pl, ch, au, de, fr, nl (code pays fourni par la source)

842-2 Hemoglobin level is associated with mortality and hospitalization in patients with severe chronic heart failure: Results from the COPERNICUS study

Stefan D. Anker, Andrew J.S. Coats, Ellen B. Roecker, Paul Mohaçsi et autres

821-1 Should beta-blockers be used before angiotensin converting enzyme inhibitors in patients with chronic heart failure? Meta-analysis of the prognostic benefit conferred by beta-blockers in patients not receiving ACE inhibitors

Henry Krum, Steven Joseph Haas, Jalal K. Ghali, Edward M. Gilbert et autres

Hemoglobin level is associated with adverse outcomes in patients with severe chronic heart failure: results from the COPERNICUS study

Stefan D. Anker, Andrew J.S. Coats, Ellen B. Roecker, Paul Mohaçsi et autres

au, us, ch (code pays fourni par la source)